Presto Embarks on Regional Market Expansion: Bringing Innovative Loyalty to E-Commerce Redemption Ecosystem to Singapore and Thailand
KUALA LUMPUR, Apr 1, 2024 – (ACN Newswire) – Presto, renowned as Malaysia’s First Loyalty E-commerce Aggregator, is proud to announce its strategic expansion into the Singapore and Thailand market. The setting up of Presto operations in these countries marks the start of the company’s regional expansion, bringing its innovative loyalty to the e-commerce redemption ecosystem to a wider audience.
Having achieved monumental success by connecting over 20 million users in Malaysia through esteemed partnerships with industry giants such as Bonus Link and Touch ‘N Go eWallet, Presto is now poised to redefine the loyalty rewards landscape on a regional scale. This expansion is led by the newly appointed Managing Director, Regional Business, Jeffry Ho, alongside dedicated Country Heads for Presto Singapore and Thailand, Donn Kwong, and Nakarin Prapaiwongs, respectively, signaling growth and opportunity for Presto’s partners and members.
Presto is Malaysia’s premier Multiple Loyalty Points Redemption Hub, redefining the loyalty rewards program by ingeniously integrating it with e-commerce redemption. With a robust connection to over 20 million loyalty members, Presto offers an unparalleled selection of over 20,000 products ranging from health and beauty, home and living, to tech and gadgets, and vouchers – all available at the convenience under one platform. This groundbreaking platform marks a significant shift in the loyalty rewards ecosystem, introducing a novel concept where loyalty points transcend their traditional role.
The process of combining points with Presto is designed to be as user-friendly with minimal tech integration from our loyalty issuers partners. Users can simply link their various loyalty program accounts through the Presto platform, and then choose how they wish to combine their points at the time of redemption. Presto’s transparent interface ensures that users have complete control over their points, enabling them to maximize the value of their rewards in a way that suits their preferences and needs.
The unique selling proposition of Presto lies in its ability to seamlessly integrate points from multiple loyalty programs, offering unprecedented flexibility to users. This means that points which were previously stranded in less frequently used accounts can now be combined with others to unlock valuable rewards. Whether it’s travel, dining, shopping, or entertainment, users can now leverage their collective points balance to enjoy a wide range of rewards, without the need to wait for a high accumulated points balance in a single program.
The unique selling proposition of Presto lies in its ability to seamlessly integrate points from multiple loyalty programs, offering unprecedented flexibility to users. This means that points which were previously stranded in less frequently used accounts can now be combined with others to unlock valuable rewards. Whether it’s travel, dining, shopping, or entertainment, users can now leverage their collective points balance to enjoy a wide range of rewards, without the need to wait for a high accumulated points balance in a single program.
At the same time, Presto is engaging in collaborations with several significant upcoming partners. This strategic move not only signifies Presto’s commitment to delivering unparalleled value and convenience to its users but also marks the beginning of an exciting new chapter in the company’s journey to revolutionize the loyalty ecosystem across the region.
Mr Cheong Chia Chou, Group CEO of Presto, commented, “The expansion of Presto into the Singapore and Thailand markets represents a significant milestone for our company. We are excited to bring our innovative loyalty to e-commerce redemption ecosystem to a wider audience, enhancing user experiences and driving regional growth. This move underscores our commitment to delivering unparalleled value and convenience to our users across the region.”
Mr Jeffry Ho, appointed as Managing Director, Regional Business, brings with him more than 20 years of regional experience in the Asia Pacific countries. His leadership, coupled with extensive knowledge of the regional market dynamics, positions Presto for unprecedented success in the region. Donn Kwong and Nakarin Prapaiwongs, appointed as Country Heads for Presto Singapore and Thailand respectively, bring their expertise in sales, partner management, and distribution channels in the Fintech, IT, and Mobile industries, ensuring customized offerings to meet the unique needs of these markets.
The setting up of Presto operations in Thailand and Singapore is just the beginning of the company’s regional expansion. Presto is committed to fostering a seamless Loyalty to E-commerce Redemption ecosystem where businesses across the region can thrive together, creating unparalleled value for all stakeholders.
Topic: Press release summary
Japan – Fujitsu Embarks on Joint Research with National Cancer Center Japan to Create New Services for Drug Development and Clinical Trials
Fujitsu today announced it has concluded a comprehensive collaborative research agreement with National Cancer Center Japan. The joint research will center on exploring ways that real-world data(1), including medical information from electronic records, can be leveraged to contribute to the development of new drugs, clinical trials, and preventive medicine in pharmaceutical companies.
Through its joint research with the National Cancer Center, Fujitsu aims to create new value through a wide range of information and analysis services by creating an anonymized personal health record scheme(2) (PHR), which includes case study information and health information on patients visiting the National Cancer Center Hospital East. Fujitsu additionally seeks to create a platform for providing pharmaceutical companies with data that can be used for drug development and preventive medicine. Fujitsu will establish a new model to process medical information from electronic medical records into highly secure statistical data to improve the efficiency of clinical trials and supports active participation in international joint clinical trials by promoting the adaptation of clinical trial data in Japan to global standards.(3)
With an eye to contributing to the wellbeing of people in society, Fujitsu will work to improve the development speed and quality of pharmaceuticals and other products that promote the health of consumers. In turn, Fujitsu will play a role in resolving issues such as the time required for clinical trials and costs, create a variety of services that contribute to areas such as preventive medicine and individualized cancer medicine, and implement these services by the end of fiscal 2021.
Background
In recent years, real-world data has been attracting increased attention in the healthcare field, and it is beginning to be used in a wide range of fields globally–from drug approval applications to the development of medical devices and preventive medicine. A variety of different data types are being used to these ends, ranging from patient electronic medical record information and medical examination information, to daily measurement data such as weight and body composition monitors(4), as well as vital information such as temperature and blood pressure that can be obtained from smart devices.
Despite the potential for such data, however, challenges remain around extracting useful information from unstructured sources like doctors’ notes, etc., and it has become necessary to develop new platforms and data extraction technologies to effectively and securely streamline the use of valuable medical data. To this end, Fujitsu has concluded a comprehensive agreement with the National Cancer Center with the ultimate goal of contributing to the speedy development of pharmaceuticals and clinical trials by pharmaceutical companies that promote the health of consumers and will start joint research in this field.
About the Joint Research
1. Overview
In collaboration with the National Cancer Center, Fujitsu is implementing three projects to utilize real-world data at the National Cancer Center Hospital East.
Verification of utilization of real-world data (real-world data share)
– In addition to medical information from the electronic medical record systems, which has been difficult to use until now, information on case studies and information on the health of local patients (PHR) is processed into a format that is easy for pharmaceutical companies to handle and provided as secure, high-quality data. The effectiveness of using real-world data in developing new AI technologies to support diagnoses and treatment will also be verified.
Establishment and validation of new clinical trial service models (DX for Clinical Trial Operations)
– Natural language analysis technology will be applied to the analysis of medical information in the electronic medical record system in order to establish a new clinical trial service model that can automatically identify appropriate clinical trial patients with overwhelming speed and accuracy. This process is presently performed manually with reference to medical information in the electronic medical record system (clinical trial patient recruitment). Through this study, the effectiveness of the system in significantly reducing the cost and duration of clinical trials, including improving the efficiency of in-hospital operations will be verified.
– Fujitsu will promote efforts to adapt clinical trial data in Japan to global standards and support active participation in international clinical trials.
Establishment of a platform for safe and secure use of medical data (common platform)
– In order to carry out these two verifications, Fujitsu will develop a platform that can safely and securely utilize medical data by converting medical information recorded as text data in the electronic medical record system into a format that can be utilized as data. This platform utilizes technology developed by Fujitsu Laboratories, Ltd., as well as data extraction technology that is being newly developed.
2. Role of Fujitsu, National Cancer Center
Fujitsu
– Development of technologies and platforms needed to utilize real-world data
– Verifying streamlining of clinical trial operations with patient recruiting function
– Coordination with national policies for the utilization of PHRs (5)
National Cancer Center
– Provision of medical data at National Cancer Center Hospital East
– Provision of know-how on clinical practice, clinical research, and clinical trials
– Verification of the contents of joint research
3. Period of Joint Research
March 16, 2021 ~ March 31, 2023
4. Location
National Cancer Center Hospital East and Exploratory Oncology Research & Clinical Trial Center
Future Plans
In the future, Fujitsu will not only collaborate with pharmaceutical companies, but also consider working with various companies that provide wellbeing-related products and services to consumers in Japan and throughout the world. Based on the results of this joint research, by the end of fiscal 2021 Fujitsu will develop platforms and services that enable the safe and secure use of real-world data and provide wellbeing to consumers. Through the provision of these platforms and services to pharmaceutical companies, Fujitsu aims to contribute to the streamlining of drug development and clinical trials.
(1) real-world data：
Data generated by daily medical care and personal health management.
(2) PHR：
A system in which individuals collect and manage their own medical information and other health-related information. Refers to information that can be subject to disclosure control at the discretion of the individual.
(3) international joint clinical trials：
A clinical trial conducted simultaneously in multiple countries or regions.
(4) weight and body composition monitors：
a measuring instrument that measures weight and body fat percentage and visceral fat levels etc.
(5) National policies:
For example, policies led by Data Health Reform Promotion Headquarters of the Ministry of Health, Labour and Welfare such as “Health, Medical, and Nursing Care Information Utilization Study Group”.
About Fujitsu
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see www.fujitsu.com.
Fujitsu Embarks on Partnership with Siemens Digital Industries Software Strengthening Global Competitiveness and Accelerating DX to Realize Smart, Sustainable Manufacturing
Fujitsu today announced an agreement to collaborate with Siemens Digital Industries Software to enhance competitiveness for its customers and strengthen and accelerate Digital Transformation (DX) in the manufacturing industry beginning with the Japanese market.
Through this collaboration, Fujitsu will initially resell industry-specific solutions from Siemens’ Xcelerator portfolio in the Japanese market, including Siemens’ Product Lifecycle Management System “Teamcenter”(1) and Manufacturing Operation Management System “Opcenter”(2), while providing solutions that draw on these capabilities in combination with Fujitsu’s brand of manufacturing solutions and services, COLMINA. With the technical support of Siemens, Fujitsu is additionally developing 3D-BOP(3) functions that seamlessly link design and assembly processes to shorten time to market and improve productivity and quality.
Going forward, Fujitsu will begin offering 3D-BOP functions to the Japanese market in July 2021. Based on the results achieved in the initial roll-out in Japan, Fujitsu will strengthen its global service provision and maintenance structure, and in April 2022, plans to expand service offering to Europe, North America, and Asia.
Facing increasingly fierce global competition in the manufacturing industry, many companies feel growing pressure to streamline operations, boost competitiveness, and find ways to contribute to international sustainability initiatives like the UN’s Sustainable Development Goals (SDGs). To this end, many have proactively promoted the use of digital technologies. In many cases, however, data used in individual processes like design, production engineering, and manufacturing is still managed separately, and because systems aren’t interconnected this data isn’t fully utilized. This in turn hinders progress toward more sustainable, efficient practices in manufacturing. To overcome these challenges and realize smart manufacturing that takes sustainability into account while remaining resistant to changes in the global business environment, companies must build the capacity to quickly introduce integrated solutions that seamlessly link planning, design, production preparation, and production processes.
Through this collaboration, Fujitsu aims to build the global capabilities needed to respond quickly to market changes and to support its customers’ competitiveness in the manufacturing industry, as well as contribute to the fulfillment of the SDGs through the acceleration of DX initiatives. Fujitsu aims to achieve this by seamlessly linking manufacturing information that is managed individually at each site and process on a global basis, using Siemens’ globally recognized solutions for the manufacturing industry. Fujitsu will also leverage the know-how and expertise it has cultivated over its years of business development and problem-solving in the manufacturing space and its track record in implementing CPS (Cyber Physical System)(4), which represents a combination of physical and computational elements in the manufacturing area.
Fujitsu will continue to support Digital Transformation (DX) in the manufacturing industry in fulfillment of its mission for its manufacturing brand, COLMINA: “Bringing innovation to manufacturing through the delivery of services that are global, open, and rapid that help to realize DX.” Fujitsu’s commitment to this mission for its COLMINA business brand will ultimately allow for the creation of new value, enhance competitiveness in the manufacturing industry, and support the realization of the Sustainable Development Goals (SDGs) for the entire society.
(1) Teamcenter:
Siemens PLM system that enables centralized management of product information through product planning, design and production preparation phases.
(2) Opcenter:
Siemens’ MES solution that digitizes quality control, planning and scheduling, operations, and visualizes manufacturing processes.
(3) 3D-BOP:
A function of managing shape data in association with design information, assembly information, manufacturing record information, etc., to facilitate data linkage between the design process and the manufacturing process.
(4) CPS (Cyber Physical System):
Data collected in the physical (real) domain is analyzed and verified in the cyber (virtual) domain, and the results are reflected in physical domain to interact with each other to solve problems.
About Fujitsu
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see www.fujitsu.com.
Topic: Press release summary
Ads
